Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Jiangxi Institute of Biological Products PB Ratio?
Jiangxi Institute of Biological ProductsHKSE:06915 +1.33%23 PB Ratio is 9.37 as of Sep. 10, 2026, which is 19% above its 10-year median of 7.85. GuruFocus rates HKSE:06915 with a GF Score™ of 23/100. The stock has 3 warning signs investors should review. Among 919 Drug Manufacturers companies, Jiangxi Institute of Biological Products ranks worse than 91.51% on this metric.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Jiangxi Institute of Biological Products PB Ratio Related Terms
Jiangxi Institute of Biological Products PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jiangxi Institute of Biological Products PB Ratio Chart
Jiangxi Institute of Biological Products Annual Data
Trend
Dec23
Dec24
Dec25
PB Ratio
0.00
0.00
0.00
Jiangxi Institute of Biological Products Semi-Annual Data
Dec23
Dec24
Dec25
PB Ratio
0.00
0.00
0.00
HKSE:06915 vs LLY, JNJ, ABBV: PB Ratio Comparison
For the Drug Manufacturers - General subindustry, Jiangxi Institute of Biological Products's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jiangxi Institute of Biological Products PB Ratio vs Drug Manufacturers Industry
Jiangxi Institute of Biological Products PB Ratio Calculation
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Jiangxi Institute of Biological Products (HKSE:06915) has a PB Ratio of 9.37 as of Sep. 10, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Jiangxi Institute of Biological Products and its competitors. This is 19% above median its historical median of 7.85. Over the past decade, Jiangxi Institute of Biological Products' PB Ratio has ranged from 2.52 to 11.49. According to the industry distribution chart, Jiangxi Institute of Biological Products ranks #841 out of 919 companies in the Drug Manufacturers industry, placing it in the top 91.5%.
Is Jiangxi Institute of Biological Products' PB Ratio too high?
Jiangxi Institute of Biological Products' current PB Ratio of 9.37 is 19% above median its 10-year median of 7.85. Over the past 10 years, this metric has ranged from a low of 2.52 to a high of 11.49. The Drug Manufacturers industry median PB Ratio is 1.96. Jiangxi Institute of Biological Products' value of 9.37 is 378.1% above this industry median. Based on the distribution chart, Jiangxi Institute of Biological Products ranks #841 out of 919 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Jiangxi Institute of Biological Products has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Jiangxi Institute of Biological Products' PB Ratio compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Jiangxi Institute of Biological Products ranks #841 out of 919 companies for PB Ratio. This places Jiangxi Institute of Biological Products in the lower half of its industry. The industry median PB Ratio is 1.96. Jiangxi Institute of Biological Products' value of 9.37 is 378.1% above this benchmark. Historically, Jiangxi Institute of Biological Products' own PB Ratio has ranged from 2.52 to 11.49 over the past decade. While the company's 10-year median is 7.85 vs. the industry median of 1.96, Jiangxi Institute of Biological Products has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.96, based on 919 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jiangxi Institute of Biological Products's current PB Ratio of 9.37 is 378.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Jiangxi Institute of Biological Products and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jiangxi Institute of Biological Products's current PB Ratio is 9.37, which is 19% above median its own 10-year median of 7.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jiangxi Institute of Biological Products stock overvalued right now?
Jiangxi Institute of Biological Products (HKSE:06915) has a current PB Ratio of 9.37. The current PB Ratio is 9.37, which is 19% above median its 10-year median of 7.85 and 378.1% above the Drug Manufacturers industry median of 1.96. Jiangxi Institute of Biological Products' overall GF Score™ is 23/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Jiangxi Institute of Biological Products (HKSE:06915), the current PB Ratio is 9.37 as of Sep. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Jiangxi Institute of Biological Products Inc is principally engaged in the business of research and development, and production and sale of human tetanus antitoxin. It operates as the provider and exporter of Human TAT in China and an antiserum platform company. Its products include biological products containing immunoglobulins or immunoglobulin F(ab')2 fragments, which are used in medical applications such as tetanus, snakebite envenoming, and rabies treatment. The majority of the company's revenue is derived from the sale of Human Tetanus Antitoxin in the Chinese mainland.
23GF Score
Get the complete analysis for HKSE:06915
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:06915 has been successfully added to your 
